298 related articles for article (PubMed ID: 18076318)
1. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma.
Sonabend AM; Dana K; Lesniak MS
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S45-50. PubMed ID: 18076318
[TBL] [Abstract][Full Text] [Related]
2. EGF receptor variant III as a target antigen for tumor immunotherapy.
Li G; Wong AJ
Expert Rev Vaccines; 2008 Sep; 7(7):977-85. PubMed ID: 18767947
[TBL] [Abstract][Full Text] [Related]
3. Tumor antigens in astrocytic gliomas.
Kurpad SN; Zhao XG; Wikstrand CJ; Batra SK; McLendon RE; Bigner DD
Glia; 1995 Nov; 15(3):244-56. PubMed ID: 8586461
[TBL] [Abstract][Full Text] [Related]
4. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapies for malignant glioma.
Lukas RV; Boire A; Nicholas MK
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S29-36. PubMed ID: 18076315
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?
Karpel-Massler G; Schmidt U; Unterberg A; Halatsch ME
Mol Cancer Res; 2009 Jul; 7(7):1000-12. PubMed ID: 19584260
[TBL] [Abstract][Full Text] [Related]
7. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.
Wikstrand CJ; Reist CJ; Archer GE; Zalutsky MR; Bigner DD
J Neurovirol; 1998 Apr; 4(2):148-58. PubMed ID: 9584952
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor type I biology and targeting in malignant gliomas.
Trojan J; Cloix JF; Ardourel MY; Chatel M; Anthony DD
Neuroscience; 2007 Mar; 145(3):795-811. PubMed ID: 17320297
[TBL] [Abstract][Full Text] [Related]
9. Molecularly targeted therapy for malignant glioma.
Sathornsumetee S; Reardon DA; Desjardins A; Quinn JA; Vredenburgh JJ; Rich JN
Cancer; 2007 Jul; 110(1):13-24. PubMed ID: 17520692
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based immunotherapy for malignant gliomas.
Akasaki Y; Black KL; Yu JS
Expert Rev Neurother; 2005 Jul; 5(4):497-508. PubMed ID: 16026233
[TBL] [Abstract][Full Text] [Related]
11. The EGFRvIII variant in glioblastoma multiforme.
Gan HK; Kaye AH; Luwor RB
J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
[TBL] [Abstract][Full Text] [Related]
12. Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.
Del Vecchio CA; Wong AJ
Curr Opin Mol Ther; 2010 Dec; 12(6):741-54. PubMed ID: 21154166
[TBL] [Abstract][Full Text] [Related]
13. Convection-enhanced delivery for treatment of brain tumors.
Ferguson SD; Foster K; Yamini B
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S79-85. PubMed ID: 18076322
[TBL] [Abstract][Full Text] [Related]
14. [Peptide vaccination therapy for malignant glioma].
Yamanaka R; Itoh K
Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
[TBL] [Abstract][Full Text] [Related]
15. Novel immunotherapeutic approaches to glioma.
Yamanaka R
Curr Opin Mol Ther; 2006 Feb; 8(1):46-51. PubMed ID: 16506525
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH
Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045
[TBL] [Abstract][Full Text] [Related]
17. Vaccines for glioblastoma and high-grade glioma.
Wheeler CJ; Black KL
Expert Rev Vaccines; 2011 Jun; 10(6):875-86. PubMed ID: 21692706
[TBL] [Abstract][Full Text] [Related]
18. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data.
Chakravarti A; Dicker A; Mehta M
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):927-31. PubMed ID: 14967452
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma.
Chang CN; Huang YC; Yang DM; Kikuta K; Wei KJ; Kubota T; Yang WK
J Clin Neurosci; 2011 Aug; 18(8):1048-54. PubMed ID: 21715171
[TBL] [Abstract][Full Text] [Related]
20. Biologic principles of immunotherapy for malignant gliomas.
Han SJ; Kaur G; Yang I; Lim M
Neurosurg Clin N Am; 2010 Jan; 21(1):1-16. PubMed ID: 19944962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
